Mysa Saad: Antiplatelets Increase Bleeding Without Reducing VTE in Cancer Patients
Mysa Saad, Internal Medicine Resident shared a post on LinkedIn about a recent article she and her colleagues co-authored, adding:
”Our new study published in Thrombosis Research:
In ambulatory patients with cancer on apixaban thromboprophylaxis:
- Concurrent antiplatelet/NSAID use increases clinically relevant bleeding (HR 1.80)
- Antiplatelets were the main driver of increased bleeding risk (HR 2.02)
- NSAIDs did not have a significant impact on bleeding risk
- No significant reduction in VTE
These results highlight the need to carefully reassess indications for concurrent antiplatelet agents/NSAIDs when considering apixaban thromboprophylaxis in patients with cancer.”
Title: Impact of concurrent antiplatelet use on the safety and efficacy of thromboprophylaxis with apixaban in patients with cancer: A post-hoc analysis of the AVERT trial
Authors: Mysa Saad, Tzu-Fei Wang, Ranjeeta Mallick, Danny Hill, Alejandro Lazo-Langner, Vicky Tagalakis, Philip S. Wells, Marc Carrier
Stay updated on all scientific advances with Hemostasis Today.
-
Aug 30, 2026, 17:13J. Meireles-Brandao: Hypertension, Inflammation and Lipoprotein Disease
-
Aug 30, 2026, 17:10Hugh Nguyen: Leading the New Era of Blood Services Across Asia Pacific
-
Aug 30, 2026, 17:09Transforming Childhood Through Access to Hemophilia Treatment – World Federation of Hemophilia
-
Aug 30, 2026, 17:07Raj Bharath: Connecting Clinicians and Researchers to Advance Transfusion Medicine
-
Aug 30, 2026, 17:04Rana Al Hrout: Free FRCPath Haematology Part 1 Exam Preparation Session
-
Aug 30, 2026, 17:02David McGlasson: A 2020 Article Reaches 8,000 Reads
-
Aug 30, 2026, 16:18Tushar Namdeo: Platelets in Different Diseases
-
Aug 30, 2026, 16:16Fatima Zafar: Anaemia – Why This “Common” Condition Should Never Be Ignored
-
Aug 30, 2026, 16:13Umeshkumar C.: Evaluating Scoring Systems and Biomarkers for DIC in Critically Ill Patients